Your browser is no longer supported. Please, upgrade your browser.
Settings
RGNX REGENXBIO Inc. daily Stock Chart
RGNX [NASD]
REGENXBIO Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own1.40% Shs Outstand37.52M Perf Week13.73%
Market Cap1.99B Forward P/E- EPS next Y-0.75 Insider Trans-26.53% Shs Float31.10M Perf Month18.58%
Income-36.50M PEG- EPS next Q-0.56 Inst Own83.60% Short Float12.21% Perf Quarter-9.47%
Sales87.00M P/S22.87 EPS this Y211.40% Inst Trans0.61% Short Ratio6.82 Perf Half Y15.99%
Book/sh13.39 P/B3.96 EPS next Y9.30% ROA-7.60% Target Price82.67 Perf Year-6.96%
Cash/sh7.60 P/C6.97 EPS next 5Y2.00% ROE-8.10% 52W Range38.56 - 85.10 Perf YTD26.41%
Dividend- P/FCF523.60 EPS past 5Y69.30% ROI16.30% 52W High-37.69% Beta0.63
Dividend %- Quick Ratio14.20 Sales past 5Y104.60% Gross Margin91.70% 52W Low37.53% ATR2.85
Employees192 Current Ratio14.20 Sales Q/Q-99.30% Oper. Margin-57.30% RSI (14)61.08 Volatility5.46% 6.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-129.10% Profit Margin-42.00% Rel Volume1.06 Prev Close53.03
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume556.17K Price53.03
Recom2.50 SMA2013.53% SMA508.46% SMA200-3.55% Volume0 Change0.00%
Jun-18-19Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19Resumed Raymond James Outperform
Jun-05-19Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19Upgrade Evercore ISI In-line → Outperform
Feb-05-19Upgrade Raymond James Outperform → Strong Buy $94
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Oct-12-17Initiated Raymond James Outperform $39
Aug-17-17Initiated Evercore ISI Outperform $25
Aug-09-17Reiterated Chardan Capital Markets Buy $50 → $55
Apr-11-17Reiterated Chardan Capital Markets Buy $35 → $50
Jun-11-19 07:00AM  REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference PR Newswire
Jun-03-19 02:32PM  Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-28-19 01:47PM  FDA approves most expensive gene therapy ever and here is its connection to Penn American City Business Journals +7.19%
11:25AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4% Zacks
May-24-19 07:46PM  Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Motley Fool +7.44%
01:14PM  REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform PR Newswire
May-15-19 07:00AM  REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies PR Newswire
May-08-19 07:00AM  REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire -8.52%
May-07-19 09:24PM  Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript Motley Fool
06:36PM  Regenxbio: 1Q Earnings Snapshot Associated Press
04:05PM  REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD PR Newswire
May-02-19 12:40PM  Is Regenxbio Inc (RGNX) A Good Stock To Buy? Insider Monkey
Apr-30-19 07:00AM  REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights PR Newswire
Apr-22-19 04:15PM  A Second Baby Died In A Gene Therapy Study Slugging This Biotech Stock Investor's Business Daily -7.80%
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
01:22PM  Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain? Simply Wall St.
Apr-17-19 07:00AM  REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer PR Newswire
Apr-15-19 04:05PM  REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting PR Newswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
Apr-03-19 08:16AM  3 Small-Cap Biotech Stocks to Watch Now Motley Fool
Mar-26-19 07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-08-19 10:40AM  Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next? Motley Fool
Mar-06-19 07:00AM  REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire -5.56%
Mar-05-19 08:44AM  REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher Zacks
Mar-04-19 10:43AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool +5.12%
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com
09:07PM  Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 09:41PM  Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights PR Newswire
09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-20-19 07:00AM  REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights PR Newswire
Feb-14-19 07:00AM  REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists PR Newswire
Feb-04-19 07:20AM  Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-31-19 07:00AM  REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease PR Newswire
Jan-29-19 12:36PM  Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-21-19 02:14PM  REGENXBIO Inc. (NASDAQ:RGNX): Time For A Financial Health Check Simply Wall St.
Jan-04-19 07:00AM  REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +10.95%
Jan-03-19 04:05PM  REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update PR Newswire -5.79%
Dec-12-18 02:58AM  Is Regenxbio Inc (RGNX) A Good Stock To Buy? Insider Monkey -6.40%
Dec-04-18 01:58PM  This Rockville biotech is getting some help from Maryland, MoCo for its new HQ American City Business Journals -9.59%
Nov-26-18 08:36AM  Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector Business Wire
08:36AM  REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector PR Newswire
Nov-16-18 01:32AM  DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire
Nov-14-18 07:00AM  FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease PR Newswire -5.89%
Nov-12-18 09:00AM  Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International Fundamental Analysis, Key Performance Indications GlobeNewswire -5.50%
Nov-07-18 05:52PM  Regenxbio: 3Q Earnings Snapshot Associated Press +5.91%
04:45PM  This Rockville biotech is expanding to a new HQ. Here are the details. American City Business Journals
04:05PM  REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II PR Newswire
04:05PM  Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facility PR Newswire
Nov-06-18 07:00AM  REGENXBIO to Present at Upcoming Investor Conferences PR Newswire
Nov-05-18 07:00AM  REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector PR Newswire
Oct-31-18 04:05PM  REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire +7.60%
Oct-29-18 09:30AM  ANIK vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Oct-26-18 06:10PM  REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting PR Newswire
Oct-22-18 07:00AM  REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors PR Newswire
Oct-18-18 09:20AM  Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-04-18 07:00AM  REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD PR Newswire
Oct-02-18 04:05PM  REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference PR Newswire -7.65%
Sep-30-18 03:15PM  Gene Therapy Could Be a Boon for This Biotech Motley Fool
Sep-28-18 11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
Sep-21-18 03:44PM  Taking Profits Early Paid Off In This Biotech Stock Investor's Business Daily
Sep-20-18 11:27AM  Why Amicus Therapeutics Is Up 10% Today Motley Fool
08:35AM  Implied Volatility Surging for REGENXBIO (RGNX) Stock Options Zacks
Sep-14-18 04:23PM  Small Caps Lead Quiet Session; Nasdaq, S&P 500 Mostly Flat; Adobe Jumps Investor's Business Daily +10.33%
Sep-12-18 12:46PM  Is REGENXBIO Incs (NASDAQ:RGNX) ROE Of 24.6% Sustainable? Simply Wall St.
Sep-06-18 04:05PM  REGENXBIO to Present at Upcoming Investor Conferences PR Newswire
Aug-31-18 08:00AM  Todays Research Reports on Stocks to Watch: INSYS Therapeutics and REGENXBIO ACCESSWIRE
Aug-30-18 07:00AM  REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease PR Newswire +10.18%
Aug-27-18 08:15AM  New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-22-18 11:50PM  Edited Transcript of RGNX earnings conference call or presentation 8-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-14-18 04:01PM  REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Aug-10-18 07:30AM  REGENXBIO Announces Pricing Of Public Offering Of Common Stock PR Newswire
Aug-09-18 08:39AM  The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings Benzinga -5.46%
Aug-08-18 04:05PM  REGENXBIO Announces Proposed Public Offering Of Common Stock PR Newswire
08:57AM  Regenxbio: 2Q Earnings Snapshot Associated Press
07:30AM  REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia PR Newswire
06:00AM  REGENXBIO, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 05:43PM  REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia PR Newswire
Aug-06-18 09:30AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
Aug-01-18 07:00AM  REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire
Jul-19-18 09:50AM  ALXN or RGNX: Which Is the Better Value Stock Right Now? Zacks
09:45AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
07:50AM  10 winners, 10 losers in this years breakout small-cap stock sector MarketWatch
Jul-16-18 08:20AM  Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE
Jul-13-18 08:15AM  Better Know Biotech: Regenxbio Inc. Motley Fool
Jul-06-18 08:01PM  3 Top Biotech Stocks to Buy in July Motley Fool
Jul-05-18 07:35AM  Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities ACCESSWIRE
Jul-04-18 08:00AM  Today's Research Reports on Trending Tickers: Tesaro and REGENXBIO ACCESSWIRE
Jul-03-18 09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool
Jun-29-18 11:40AM  5 Top Performing Stocks of the Best ETF of 1H2018 Zacks
Jun-26-18 09:30AM  ALXN vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Jun-25-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko Petroleum, CTS, REGENXBIO, and TripAdvisor New Research Emphasizes Economic Growth GlobeNewswire
Jun-20-18 08:44AM  REGENXBIO (RGNX) in Focus: Stock Moves 6.2% Higher Zacks +10.32%
Jun-13-18 07:48AM  Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111 Benzinga
Jun-12-18 05:36PM  REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I PR Newswire
Jun-11-18 04:05PM  REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis PR Newswire
Jun-05-18 10:50AM  Why REGENXBIO Inc (NASDAQ:RGNX) Delivered An Inferior ROE Compared To The Industry Simply Wall St. +8.99%
08:05AM  Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index Benzinga
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Simpson CurranSVP, Product Development & CTOMay 28Option Exercise22.0018,000396,00057,500May 30 04:56 PM
Simpson CurranSVP, Product Development & CTOMay 28Sale50.0018,000900,00039,500May 30 04:56 PM
Mills Kenneth T.President and CEOMay 20Option Exercise0.8515,00012,750261,000May 22 04:18 PM
Mills Kenneth T.President and CEOMay 20Sale42.9915,000644,866246,000May 22 04:18 PM
Mills Kenneth T.President and CEOApr 22Option Exercise0.8515,00012,750261,000Apr 24 04:20 PM
Mills Kenneth T.President and CEOApr 22Sale50.4415,000756,566246,000Apr 24 04:20 PM
Christmas Patrick J.SVP, General CounselApr 18Option Exercise14.265,00071,2978,006Apr 22 04:17 PM
Christmas Patrick J.SVP, General CounselApr 18Sale53.235,000266,1613,006Apr 22 04:17 PM
Danos OlivierChief Scientific OfficerApr 15Option Exercise20.352,00040,7008,500Apr 17 04:19 PM
Danos OlivierChief Scientific OfficerApr 15Sale52.662,000105,3206,500Apr 17 04:19 PM
Vasista VittalChief Financial OfficerMar 21Sale60.7510,000607,539229,215Mar 25 12:32 PM
Mills Kenneth T.President and CEOMar 19Option Exercise0.8515,00012,750261,000Mar 21 04:17 PM
Mills Kenneth T.President and CEOMar 19Sale58.5315,000877,989246,000Mar 21 04:17 PM
Danos OlivierChief Scientific OfficerMar 12Option Exercise20.355,000101,7506,500Mar 14 04:17 PM
Vasista VittalChief Financial OfficerMar 05Sale60.013,068184,111239,215Mar 07 04:23 PM
Simpson CurranSVP, Product Development & CTOFeb 25Option Exercise35.805,300189,74044,800Feb 27 05:35 PM
Simpson CurranSVP, Product Development & CTOFeb 25Sale54.055,300286,46539,500Feb 27 05:35 PM
Mills Kenneth T.President and CEOFeb 15Sale47.2915,000709,284246,000Feb 19 04:19 PM
Mills Kenneth T.President and CEOFeb 14Option Exercise0.8515,00012,750261,000Feb 19 04:19 PM
Vasista VittalChief Financial OfficerFeb 07Option Exercise0.85120,000102,000242,283Feb 11 04:20 PM
Simpson CurranSVP, Product Development & CTOFeb 05Option Exercise24.4343,8321,070,65883,332Feb 07 04:18 PM
Simpson CurranSVP, Product Development & CTOFeb 05Sale50.0843,8322,195,10739,500Feb 07 04:18 PM
Mills Kenneth T.President and CEOFeb 01Option Exercise0.8545,00038,250246,000Feb 05 04:21 PM
Mills Kenneth T.President and CEOJan 15Sale43.8515,000657,698201,000Jan 17 04:18 PM
Christmas Patrick J.SVP, General CounselDec 18Option Exercise12.105,00060,5007,669Dec 20 04:27 PM
Christmas Patrick J.SVP, General CounselDec 18Sale47.545,000237,6982,669Dec 20 04:27 PM
Mills Kenneth T.President and CEODec 17Sale46.7315,000700,927216,000Dec 19 04:20 PM
Vasista VittalChief Financial OfficerDec 17Sale46.357,500347,650122,283Dec 19 04:32 PM
Yoo StephenChief Medical OfficerDec 03Option Exercise0.8520,41417,35220,414Dec 06 04:22 PM
Yoo StephenChief Medical OfficerDec 03Sale60.1320,4141,227,4120Dec 06 04:22 PM
Mills Kenneth T.President and CEODec 03Sale60.4020,0001,208,087231,000Dec 06 04:19 PM
Danos OlivierChief Scientific OfficerNov 30Option Exercise20.351,50030,5251,500Dec 04 04:19 PM
BESHAR LUKE MDirectorNov 29Option Exercise3.7612,78448,06812,784Dec 03 04:19 PM
BESHAR LUKE MDirectorNov 29Sale65.0012,784830,9600Dec 03 04:19 PM
BESHAR LUKE MDirectorNov 27Option Exercise18.4718,786346,90818,786Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 27Sale65.0318,7861,221,6540Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 26Option Exercise49.451,72185,1031,721Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 26Sale65.001,721111,8650Nov 28 04:20 PM
Mills Kenneth T.President and CEONov 26Sale64.1720,0001,283,355251,000Nov 28 04:18 PM
Mills Kenneth T.President and CEONov 21Sale61.4415,000921,660271,000Nov 26 04:17 PM
BESHAR LUKE MDirectorNov 20Option Exercise9.0721,176191,96321,176Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 20Sale60.3821,1761,278,6070Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 19Option Exercise23.7812,116288,13812,116Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 19Sale60.5512,116733,6020Nov 21 04:26 PM
Simpson CurranSVP, Technical OperationsNov 16Option Exercise22.0032,882723,40472,382Nov 20 04:19 PM
Simpson CurranSVP, Technical OperationsNov 16Sale63.7632,8822,096,41939,500Nov 20 04:19 PM
Vasista VittalChief Financial OfficerNov 15Sale60.297,500452,206129,783Nov 19 04:16 PM
Christmas Patrick J.SVP, General CounselNov 07Sale72.0615,0001,080,9002,669Nov 09 04:20 PM
Yoo StephenChief Medical OfficerNov 05Option Exercise0.8520,41417,35220,414Nov 07 06:02 PM
Yoo StephenChief Medical OfficerNov 05Sale68.2820,4141,393,9330Nov 07 06:02 PM
Mills Kenneth T.President and CEONov 05Sale68.2520,0001,364,902306,000Nov 07 06:00 PM
Vasista VittalChief Financial OfficerNov 02Option Exercise15.5753,741837,009191,024Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 02Sale70.2653,7413,775,843137,283Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 01Option Exercise8.3719,677164,654156,960Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 01Sale70.0419,6771,378,177137,283Nov 05 04:20 PM
Yoo StephenChief Medical OfficerOct 29Option Exercise0.8520,41417,35220,414Oct 31 04:22 PM
Yoo StephenChief Medical OfficerOct 29Sale62.3720,4141,273,2120Oct 31 04:22 PM
Christmas Patrick J.SVP, General CounselOct 18Option Exercise12.105,00060,50022,669Oct 22 04:16 PM
Christmas Patrick J.SVP, General CounselOct 18Sale61.785,000308,89017,669Oct 22 04:16 PM
Simpson CurranSVP, Technical OperationsOct 16Option Exercise21.0962,3091,314,22386,017Oct 18 04:24 PM
Yoo StephenChief Medical OfficerOct 16Option Exercise0.8510,4148,85210,414Oct 17 04:29 PM
Simpson CurranSVP, Technical OperationsOct 16Sale60.8562,3093,791,50339,500Oct 18 04:24 PM
Yoo StephenChief Medical OfficerOct 16Sale61.1810,414637,1290Oct 17 04:29 PM
Yoo StephenChief Medical OfficerOct 15Option Exercise0.8510,0008,50010,000Oct 17 04:29 PM
Yoo StephenChief Medical OfficerOct 15Sale59.3410,000593,4120Oct 17 04:29 PM
Vasista VittalChief Financial OfficerOct 15Sale59.377,500445,275137,283Oct 17 04:24 PM
Mills Kenneth T.President and CEOOct 15Sale59.357,510445,745326,000Oct 17 04:17 PM
Danos OlivierChief Scientific OfficerOct 08Option Exercise20.3520,000407,00020,000Oct 10 04:20 PM
Danos OlivierChief Scientific OfficerOct 08Sale63.8020,0001,275,9140Oct 10 04:20 PM
Vasista VittalChief Financial OfficerSep 17Option Exercise0.8530,00025,500144,783Sep 19 04:26 PM
Vasista VittalChief Financial OfficerSep 17Sale74.867,500561,472114,783Sep 19 04:26 PM
Mills Kenneth T.President and CEOSep 17Sale74.917,510562,564333,510Sep 19 04:24 PM
Mills Kenneth T.President and CEOAug 27Option Exercise0.85145,000123,250348,530Aug 29 04:20 PM
Mills Kenneth T.President and CEOAug 27Sale66.467,510499,118341,020Aug 29 04:20 PM
Christmas Patrick J.SVP, General CounselAug 20Option Exercise12.105,00060,50022,669Aug 22 04:15 PM
Christmas Patrick J.SVP, General CounselAug 20Sale65.965,000329,80617,669Aug 22 04:15 PM
Vasista VittalChief Financial OfficerAug 15Sale65.437,500490,710122,283Aug 17 04:17 PM
Vasista VittalChief Financial OfficerJul 16Sale75.547,500566,522129,783Jul 18 04:16 PM
Mills Kenneth T.President and CEOJun 20Sale66.205,000331,018203,530Jun 22 04:15 PM